Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates

Aim Surgery is an important therapeutic option for Crohn's disease. The need for first bowel surgery seems to have decreased with the introduction of tumour necrosis factor inhibitors (TNFi; adalimumab or infliximab). However, the impact of TNFi on the need for intestinal surgery in Crohn'...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Colorectal disease 2022-04, Vol.24 (4), p.470-483
Hauptverfasser:	Eberhardson, Michael, Myrelid, Pär, Söderling, Jonas K., Ekbom, Anders, Everhov, Åsa H., Hedin, Charlotte R. H., Neovius, Martin, Ludvigsson, Jonas F., Olén, Ola, Strid, Hans, Hjortswang, Henrik, Olsson, Malin, Björk, Jan, Bengtsson, Jonas L., Halfvarson, Jonas, Andersson, Marie A., Karling, Pontus, Rejler, Martin, Jäghult, Susanna, Fagerberg, Ulrika L., Grip, Olof, Nordenvall, Caroline
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - therapeutic use biologics bowel surgery Clinical Medicine Cohort Studies Crohn Disease - drug therapy Crohn Disease - epidemiology Crohn Disease - surgery Crohn's disease Gastroenterologi Gastroenterology and Hepatology Humans Infliximab Infliximab - therapeutic use Intestine Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Monoclonal antibodies Original Patients Reumatologi och inflammation Rheumatology and Autoimmunity Surgery Treatment Outcome Tumor Necrosis Factor Inhibitors - therapeutic use Tumor Necrosis Factor-alpha Tumor necrosis factor-TNF Tumor necrosis factor-α Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!